Kardigan (KARD) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.40

Estimate

-$1.04

Surprise

+61.5%

Score today

5.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Kardigan (KARD) reported a narrower loss than forecast — adjusted EPS of -$0.40 against the -$1.04 estimate (a 61.5% beat on a still-unprofitable quarter).

• Kardigan Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-12
• Kardigan Q3 EPS $(0.64) Beats $(0.77) Estimate — benzinga, 2026-11-12
• Kardigan to Participate in the Jefferies Global Healthcare Conference — fiscal.ai, 2026-11-11

TrendMatrix currently rates KARD Sell at 5.8/10; no pre/post engine snapshot brackets this report.

1 of the last 1 quarters beat the estimate; this quarter's +61.5% surprise compares with a +61.5% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$14.12

Price target

$35.78

Stop

$13.13

Upside to target

+153.4%

Reward-to-risk

10.2:1

Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.32B

P/E (fwd)

-3.4

52-week range

$12.23–$27.00

Off 52-week high

47.7%

RSI (14)

57

Volume vs avg

0.68×

Score today

5.8/10